Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 2, 2026, 8:04 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 595 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: E=Placebo Clear all
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Safety and Preliminary Efficacy of Lipoxin Analog BLXA4-ME Oral Rinse for the Treatment of Gingivitis

NCT02342691
View directory record Official record
Conditions
Gingival Inflammation
Interventions
BLXA4, Placebo oral rinse
Drug
Lead sponsor
The Forsyth Institute
Other
Eligibility
18 Years to 65 Years
Enrollment
127 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2019
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 19, 2023 · Synced Sep 2, 2026, 8:04 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Neural Mechanisms of Interpersonal Expectations on Negative Affect

NCT06980090
View directory record Official record
Conditions
Negative Affectivity, Non-invasive Brain Stimulation, Placebo Effect, Expectations
Interventions
Session A: Positive Placebo + Active tTIS, Session B: Positive Placebo + Sham tTIS, Session C: Negative Placebo + Active tTIS, Session D: Negative Placebo + Sham tTIS, Session E: On-Placebo + Sham tTIS, Session F: Off-Placebo + Sham tTIS
Behavioral
Lead sponsor
Trustees of Dartmouth College
Other
Eligibility
18 Years to 55 Years
Enrollment
196 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
1
States / cities
Hanover, New Hampshire
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Sep 2, 2026, 8:04 AM EDT
Completed Not applicable Interventional Results available

Trial of Glutamine and Antioxidant Supplementation in Critically Ill Patients

NCT00133978
View directory record Official record
Conditions
Critical Illness, Sepsis, Multiple Organ Failure
Interventions
Glutamine, Antioxidants, Glutamine + Antioxidants, Placebo
Other
Lead sponsor
Daren K. Heyland
Other
Eligibility
18 Years and older
Enrollment
1,223 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
5
States / cities
Aurora, Colorado • Louisville, Kentucky • Dayton, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 6, 2021 · Synced Sep 2, 2026, 8:04 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Safety And Tolerability Of Multiple Doses Of PF-04950615 (RN316) In Subjects With Hypercholesterolemia

NCT01243151
View directory record Official record
Conditions
Hypercholesterolemia, Dyslipidemia
Interventions
PF-04950615 (RN316)
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 80 Years
Enrollment
68 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
9
States / cities
Culver City, California • Glendale, California • Miami, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 21, 2019 · Synced Sep 2, 2026, 8:04 AM EDT
Terminated Phase 2 Interventional Results available

Study to Evaluate Botulinum Neurotoxin Serotype E (EB-001) in Reducing Musculoskeletal Pain in Abdominoplasty

NCT03429556
View directory record Official record
Conditions
Abdominoplasty
Interventions
Botulinum Neurotoxin Serotype E, Placebo
Biological · Drug
Lead sponsor
Allergan
Industry
Eligibility
23 Years to 55 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
2
States / cities
Pasadena, California
Source: ClinicalTrials.gov public record
Updated Aug 4, 2019 · Synced Sep 2, 2026, 8:04 AM EDT
Terminated Phase 2 Interventional Results available

PROCLAIM -- Misoprostol in the Prevention of Recurrent CDI Prevent Recurrence of Clostridium Difficile Infection With Misoprostol

NCT03617172
View directory record Official record
Conditions
Clostridium Difficile
Interventions
Misoprostol 100Mcg Tab, Placebo
Drug · Other
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
3
States / cities
St Louis, Missouri • Chapel Hill, North Carolina • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 29, 2022 · Synced Sep 2, 2026, 8:04 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Study of BBT002 in Healthy Volunteers (HVs) and in Adult Patients With Chronic Obstructive Pulmonary Disease (COPD) or Chronic Rhiosininusitis With Nasal Polyps (CRSwNP)

NCT06944925
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
BBT002, Placebo
Drug
Lead sponsor
Bambusa Therapeutics
Industry
Eligibility
18 Years to 80 Years
Enrollment
286 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
3
States / cities
Bowling Green, Kentucky • Owensboro, Kentucky • New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Sep 2, 2026, 8:04 AM EDT
Completed Phase 2 Interventional Results available

Double-Blind, Placebo-Controlled Study of Two Doses of EPA-E in Patients With Non Alcoholic Steatohepatitis (NASH)

NCT01154985
View directory record Official record
Conditions
Steatohepatitis
Interventions
Placebo capsule, EPA-E 300 mg capsule
Drug
Lead sponsor
Mochida Pharmaceutical Company, Ltd.
Industry
Eligibility
18 Years and older
Enrollment
243 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
33
States / cities
Dothan, Alabama • Tucson, Arizona • Anaheim, California + 27 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2014 · Synced Sep 2, 2026, 8:04 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Learn About Study Medicine Called PF-07261271 in Healthy People

NCT05536440
View directory record Official record
Conditions
Healthy
Interventions
PF-07261271, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
4
States / cities
Lake Forest, California • Tustin, California • Eatontown, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2025 · Synced Sep 2, 2026, 8:04 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Dental Pain Study of Analgesics in Patients Undergoing Molar Removal

NCT03652818
View directory record Official record
Conditions
Dental Pain
Interventions
Pre-Op pregabalin, Pre-Op Placebo 1, Post-Op pregabalin, Post-Op Placebo 1, Post-Op Placebo 2, Post-Op acetaminophen
Drug
Lead sponsor
Nevakar, Inc.
Industry
Eligibility
17 Years to 55 Years
Enrollment
115 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Nov 22, 2021 · Synced Sep 2, 2026, 8:04 AM EDT
Completed Phase 2 Interventional Results available

Acetaminophen/Naproxen Sodium Dose Ranging Study

NCT04447040
View directory record Official record
Conditions
Pain
Interventions
Acetaminophen/naproxen sodium Dose A, Acetaminophen/naproxen sodium Dose B, Acetaminophen/naproxen sodium Dose C, Acetaminophen/naproxen sodium Dose D, Acetaminophen/naproxen sodium Dose E, Placebo
Drug
Lead sponsor
Johnson & Johnson Consumer Inc., McNeil Consumer Healthcare Division
Industry
Eligibility
17 Years to 50 Years
Enrollment
304 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Mar 23, 2025 · Synced Sep 2, 2026, 8:04 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Safety and Efficacy Study of RT001 to Treat Moderate to Severe Lateral Canthal Lines

NCT00968825
View directory record Official record
Conditions
Lateral Canthal Lines, Crow's Feet, Facial Wrinkles
Interventions
Botulinum Toxin Type A, Placebo
Drug
Lead sponsor
Revance Therapeutics, Inc.
Industry
Eligibility
30 Years to 60 Years
Enrollment
73 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Nov 18, 2013 · Synced Sep 2, 2026, 8:04 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

A(H7N9) VLP Antigen Dose-Ranging Study With Matrix-M1™ Adjuvant

NCT02078674
View directory record Official record
Conditions
Influenza (Pandemic)
Interventions
Monovalent Avian Influenza VLP (H7N9), Matrix-M1™ adjuvant, Placebo
Biological
Lead sponsor
Novavax
Industry
Eligibility
18 Years to 64 Years
Enrollment
610 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
5
States / cities
Walnut Creek, California • Miami, Florida • Meridian, Idaho + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2016 · Synced Sep 2, 2026, 8:04 AM EDT
Completed Phase 3 Interventional Results available

Rosiglitazone (Extended Release Tablets) As Monotherapy In Subjects With Mild To Moderate Alzheimer's Disease

NCT00428090
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Rosiglitazone
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
50 Years to 90 Years
Enrollment
862 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
41
States / cities
Phoenix, Arizona • Los Angeles, California • Newport Beach, California + 34 more
Source: ClinicalTrials.gov public record
Updated May 18, 2017 · Synced Sep 2, 2026, 8:04 AM EDT
Active, not recruiting Phase 1 Interventional

Study to Evaluate Safety, Tolerability and Efficacy of Oral E-B-FAHF-2 in Mild-to-Moderate Crohn's Disease

NCT03992469
View directory record Official record
Conditions
Crohn's Disease
Interventions
EBFAHF-2, Placebo
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years to 60 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 22, 2025 · Synced Sep 2, 2026, 8:04 AM EDT
Active, not recruiting Phase 1 Interventional

A Study of LY3971297 in Healthy Participants

NCT06148272
View directory record Official record
Conditions
Healthy, Obesity, Hypertension
Interventions
LY3971297, Placebo, LY3971297 IV
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 75 Years
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
3
States / cities
Anaheim, California • Miami, Florida • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Sep 2, 2026, 8:04 AM EDT
Completed Phase 2 Interventional

Safety Study of BMS-770767 in Subjects With Type 2 Diabetes

NCT01046422
View directory record Official record
Conditions
Diabetes Type 2
Interventions
BMS-770767, Placebo, Metformin
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 75 Years
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
2
States / cities
Lomita, California • Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Oct 11, 2015 · Synced Sep 2, 2026, 8:04 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

A Study to Assess Multiple Ascending Dose, Drug-Drug Interaction, and Asian Pharmacokinetic Study of ABBV-1088

NCT06579300
View directory record Official record
Conditions
Healthy Volunteer
Interventions
ABBV-1088, Placebo for ABBV-1088, Itraconazole (ITZ)
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
2
States / cities
Anaheim, California • Grayslake, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 29, 2025 · Synced Sep 2, 2026, 8:04 AM EDT
Completed Phase 1 Interventional

A Phase 1 Open-Label Study of E7974 Administered on Days 1 and 15 of a 28-Day Cycle in Patients With Solid Malignancies

NCT00130169
View directory record Official record
Conditions
Cancer, Malignant Tumors
Interventions
E7974
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
2
States / cities
Las Vegas, Nevada • Stony Brook, New York
Source: ClinicalTrials.gov public record
Updated Jun 30, 2015 · Synced Sep 2, 2026, 8:04 AM EDT
Completed Phase 2 Interventional Results available

Green Tea or Polyphenon E in Preventing Lung Cancer in Former Smokers With Chronic Obstructive Pulmonary Disease

NCT00363805
View directory record Official record
Conditions
Lung Cancer Prevention
Interventions
green tea, Polyphenon E, placebo
Dietary Supplement · Drug · Other
Lead sponsor
Sherry Chow
Other
Eligibility
40 Years to 80 Years
Enrollment
178 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
3
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Nov 27, 2013 · Synced Sep 2, 2026, 8:04 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Placebo-controlled Single Dose Study to Evaluate Safety and Pharmacokinetics of GMI-1271 in Healthy Volunteers

NCT02168595
View directory record Official record
Conditions
Healthy Adult Subjects
Interventions
GMI-1271, Placebo
Drug
Lead sponsor
GlycoMimetics Incorporated
Industry
Eligibility
19 Years to 60 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Feb 26, 2018 · Synced Sep 2, 2026, 8:04 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

SAD Study of IA-14069

NCT05317741
View directory record Official record
Conditions
Healthy
Interventions
IA-14069, Placebo
Drug
Lead sponsor
ILAb Co., Ltd.
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Jan 3, 2023 · Synced Sep 2, 2026, 8:04 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of JNJ-70033093 (BMS-986177) in Healthy Adult Participants

NCT04223349
View directory record Official record
Conditions
Healthy
Interventions
JNJ-70033093, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 26, 2025 · Synced Sep 2, 2026, 8:04 AM EDT
Completed Phase 3 Interventional Results available

Rosiglitazone (Extended Release Tablets) As Adjunctive Therapy In Subjects With Mild To Moderate Alzheimer's Disease

NCT00348140
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Rosiglitazone Extended Release 2mg, Rosiglitazone Extended Release 8mg, Placebo
Drug · Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
50 Years to 90 Years
Enrollment
1,468 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
49
States / cities
Sun City, Arizona • Tucson, Arizona • Little Rock, Arkansas + 44 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2017 · Synced Sep 2, 2026, 8:04 AM EDT